Beta Bionics (NASDAQ:BBNX) Stock: Insider Mark Hopman Sells 821 Shares

Key Points

• Insider selling: Mark Hopman sold 821 Beta Bionics shares at an average price of $20, generating $16,420. He retained 54,513 shares and has made several additional sales since September.
• Stock and earnings: BBNX fell 16.5% to $17.85, despite reporting third-quarter revenue of $35.51 million and an adjusted loss of $0.52 per share, narrowly beating analyst estimates.
• Investor risks and outlook: The company faces securities-fraud litigation allegations related to iLet device disclosures, safety, and reported complaints, while analysts maintain a “Moderate Buy” consensus with an average price target of $23.69.

Beta Bionics, Inc. (NASDAQ:BBNX - Get Free Report) insider Mark Hopman sold 821 shares of the business's stock in a transaction dated Monday, October 26th. The stock was sold at an average price of $20.00, for a total transaction of $16,420.00. Following the completion of the sale, the insider directly owned 54,513 shares of the company's stock, valued at $1,090,260. The trade was a 1.48% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Mark Hopman also recently made the following trade(s):

• On Wednesday, October 14th, Mark Hopman sold 775 shares of Beta Bionics stock. The stock was sold at an average price of $17.35, for a total value of $13,446.25.
• On Thursday, October 1st, Mark Hopman sold 370 shares of Beta Bionics stock. The stock was sold at an average price of $18.96, for a total value of $7,015.20.
• On Wednesday, September 16th, Mark Hopman sold 30,779 shares of Beta Bionics stock. The shares were sold at an average price of $20.13, for a total value of $619,581.27.
• On Wednesday, September 9th, Mark Hopman sold 36,870 shares of Beta Bionics stock. The shares were sold at an average price of $18.46, for a total value of $680,620.20.
• On Wednesday, September 2nd, Mark Hopman sold 5,327 shares of Beta Bionics stock. The shares were sold at an average price of $19.11, for a total value of $101,798.97.

Beta Bionics Trading Down 16.5%

NASDAQ BBNX traded down $3.54 on Wednesday, hitting $17.85. 2,462,073 shares of the stock traded hands, compared to its average volume of 1,183,075. The stock has a 50-day moving average of $19.23 and a 200 day moving average of $14.97. Beta Bionics, Inc. has a twelve month low of $8.80 and a twelve month high of $32.71. The company has a market capitalization of $803.07 million, a P/E ratio of -10.82 and a beta of 3.39.

Beta Bionics (NASDAQ:BBNX - Get Free Report) last issued its earnings results on Tuesday, October 27th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.01. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%. The company had revenue of $35.51 million during the quarter. As a group, equities research analysts expect that Beta Bionics, Inc. will post -2.02 earnings per share for the current year.

More Beta Bionics News

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Beta Bionics reported third-quarter 2026 revenue of approximately $35.5 million, ahead of the roughly $34.7 million analyst estimate. The company’s adjusted loss of $0.52 per share also narrowly beat the consensus estimate of a $0.53 loss. Beta Bionics Q3 earnings report
• Neutral Sentiment: Multiple law firms are publicizing a November 3, 2026 deadline for investors to seek appointment as lead plaintiff in the pending litigation. The case covers investors who purchased Beta Bionics securities from July 30, 2025, through February 24, 2026. These notices are largely duplicative and do not represent separate lawsuits or new operating developments. Class action deadline notice
• Negative Sentiment: The complaint alleges that Beta Bionics and certain executives misled investors about the safety, efficacy, and commercial performance of its iLet medical device. Reported allegations include failure to disclose a June 2025 FDA Form 483 and more than 18,000 unreported iLet complaints. The allegations have not been proven, but they raise potential regulatory, product-liability, litigation-cost, and reputational risks. Beta Bionics securities-fraud lawsuit report
• Negative Sentiment: The lawsuit follows a reported collapse of more than 37% in BBNX, with legal notices linking successive disclosures about the iLet device to a cumulative $23.09 per-share decline. Continued litigation headlines and uncertainty around product safety may keep volatility elevated and weigh on investor sentiment. Beta Bionics investor class action report

Analysts Set New Price Targets

A number of research firms have commented on BBNX. Leerink Partners lifted their price objective on shares of Beta Bionics from $24.00 to $27.00 and gave the stock an "outperform" rating in a report on Monday, September 14th. Bank of America increased their target price on shares of Beta Bionics from $18.00 to $20.00 and gave the stock a "neutral" rating in a report on Tuesday, September 15th. Barclays initiated coverage on shares of Beta Bionics in a research report on Tuesday, October 6th. They issued an "overweight" rating and a $30.00 price target on the stock. Jefferies Financial Group began coverage on shares of Beta Bionics in a report on Monday, October 12th. They issued a "buy" rating and a $30.00 price target for the company. Finally, William Blair initiated coverage on shares of Beta Bionics in a report on Friday, August 21st. They issued a "market perform" rating for the company. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $23.69.

Institutional Trading of Beta Bionics

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Legal & General Group Plc bought a new position in Beta Bionics during the 2nd quarter worth $62,000. The Manufacturers Life Insurance Company acquired a new stake in Beta Bionics in the second quarter worth $172,000. Ieq Capital LLC acquired a new stake in Beta Bionics in the second quarter worth $229,000. Quantbot Technologies LP bought a new stake in Beta Bionics in the second quarter valued at $264,000. Finally, Man Group plc bought a new stake in Beta Bionics in the second quarter valued at $419,000.

About Beta Bionics

Beta Bionics, Inc NASDAQ: BBNX is a medical technology company focused on developing and commercializing automated insulin-delivery systems for people with insulin-dependent diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to help manage blood glucose levels with limited user input.

The iLet Bionic Pancreas combines a wearable insulin pump with continuous glucose monitoring technology and adaptive dosing algorithms. The system is designed to automatically adjust insulin delivery based on an individual's glucose readings and requires users to provide relatively simple meal announcements rather than calculate precise carbohydrate amounts.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.